Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

BACKGROUND:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the ef...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2018-01, Vol.137 (4), p.338-350
Main Authors: Bonaca, Marc P, Nault, Patrice, Giugliano, Robert P, Keech, Anthony C, Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A, Jukema, J Wouter, Lewis, Basil S, Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S
Format: Article
Language:English
Subjects:
Aged
Amputation
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Biomarkers - blood
Cholesterol, LDL - blood
Down-Regulation
Dyslipidemias - blood
Dyslipidemias - diagnosis
Dyslipidemias - drug therapy
Dyslipidemias - mortality
Female
Humans
Limb Salvage
Male
Middle Aged
Peripheral Arterial Disease - blood
Peripheral Arterial Disease - diagnosis
Peripheral Arterial Disease - mortality
Peripheral Arterial Disease - therapy
Proprotein Convertase 9 - antagonists & inhibitors
Proprotein Convertase 9 - metabolism
Risk Factors
Serine Proteinase Inhibitors - adverse effects
Serine Proteinase Inhibitors - therapeutic use
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events. METHODS:FOURIER was a randomized trial of evolocumab versus placebo in 27 564 patients with atherosclerotic disease on statin therapy followed for a median of 2.2 years. Patients were identified as having PAD at baseline if they had intermittent claudication and an ankle brachial index of
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.117.032235